Assessment of the Efficacy and Tolerability of Combined Therapy with Calcipotriol and Microneedling in Patients with Vitiligo: A Prospective Study

Background: Vitiligo is a chronic dermatosis characterized by depigmented patches and significantly affecting the patient's psychoemotional state. The prevalence of vitiligo in dermatological practice is increasing, while the need for well-tolerated and effective combination treatment methods remains relevant.

The aim: To evaluate the efficacy and tolerability of combination therapy comprising calcipotriol and microneedling in patients with stable non-segmental vitiligo.

Methods: In a pilot prospective study, 15 patients (9 women and 6 men; mean age 18–60 years) with stable non-segmental vitiligo participated. All patients underwent microneedling once weekly, followed by daily application of calcipotriol throughout the entire treatment period. The total study duration was 16 weeks (12 weeks of therapy and 4 weeks of follow-up). The following assessments were used: Vitiligo Area Scoring Index (VASI), a visual analogue scale for repigmentation (G0–G4), Dermatology Life Quality Index (DLQI), and Numeric Rating Scale (NRS, 0–10 points) for pain intensity evaluation.

Results: After 12 weeks of therapy, the relative improvement in VASI was 44.4%, and repigmentation >25% was achieved in 86.7% of patients. A total of 38 adverse events were recorded in 73.3% of patients, all of mild severity (mainly transient erythema, itching, and pain). No serious adverse events were observed, and no patient discontinued treatment. Pain intensity during procedures was low (median NRS score of 2.0 points). A statistically significant improvement in quality of life was also noted: a reduction in DLQI score by 4 points (40%).

Conclusion: Combination therapy with microneedling and calcipotriol for the treatment of stable non-segmental vitiligo is an effective method with good tolerability and patient adherence.